Trial Profile
A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms HERA
- Sponsors Chugai Pharmaceutical; Roche
- 06 Jun 2023 Results of pooled analysis from NCT00045032, ISRCTN76560285, NCT00005970, NCT00004067, NCT00054587, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 28 Aug 2020 Results (n=1770) of pooled analysis assessing long-term outcomes (iDFS and OS) of patients from APT trial (NCT00542451) vs matched external controls from five studies ((BCIRG 006 [NCT00021255], NSABP-B31 [NCT00004067], HERA [NCT00045032], N-9831 [NCT00005970], and APHINITY [NCT01358877])), published in the Annals of Oncology.
- 01 Mar 2020 Sub group analysis results (n=1633) evaluating the effect of Postmastectomy radiation therapy (PMRT), published in the International Journal of Radiation Oncology, Biology, Physics.